Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

By Yahoo! Finance | 3 weeks ago

Gilead Sciences Inc. faced a setback with the FDA halting studies of some HIV drugs due to safety concerns. Despite this, the company continues to work on other HIV treatments and new drug combinations to maintain revenue.

Did you find this insightful?